Quote:
Originally Posted by proton I have already stated that no findings have been finalised, considering the early stage in the experience that we find ourselves in. However, that doesn't mean no treatments are not being TRIED. |
Not entirely true. The findings with Remdesivir have been more than finalised by now with evidence that it merely reduced hospital stay by 3 to 4 days as compared with "standard of care" with no statistically significant impact on mortality. At this point of time, I'm more aware of any NEW treatment that is currently being tried.
Quote:
Originally Posted by proton As a potential end user, however, and as someone feeling the need not to park my brains outside before I enter the hospital, I must at least know the usefulness of a treatment before allowing it to be used on me, in case I fall victim to the virus. Right now, if I were to be asked if I wanted to be administered remdesivir, I know enough to refuse it. In my situation, that's what counts, right? |
Let's assume you don't park your brains outside the hospital, but do you study the aetiology, pathophysiology, clinical presentations, differential diagnosis, diagnostic modalities, drug pharmacokinetics and pharmacodynamics, types of adverse drug reactions (drug alone, drug-drug, drug-food), complications, prognosis and therapeutic cure rates before accepting any treatment? Let's say even if you did, that's your personal situation - it cannot be applied on a large scale, let alone that of a pandemic.
Quote:
Originally Posted by proton The details of how it works and how it has stopped working, though I can provide it, albeit an empirical report, really doesn't matter does it? If someone on this thread wanted a peer reviewed, double blind verified study, it's not available at this stage, right? |
Please provide a scientific supported (even if hypothesised) report of the same. Yes, because it does matter. As far as your concern of trials goes, read on.
On February 5, 2020, a phase 3 randomized, quadruple-blind, placebo-controlled clinical trial was registered at Capital Medical University, with the goal to determine safety and efficacy of remdesivir in patients with mild to moderate SARS-CoV-2 infection (NCT04252664, since suspended).
A day later, a second trial (NCT04257656, since terminated) was registered at the same location, focused on patients with advanced COVID-19 respiratory disease.
The National Institute of Allergies and Infectious Diseases (NIAID), NIH initiated the Adaptive COVID-19 Treatment Trial (ACTT), a double-blind, randomized, placebo-controlled phase 3 trial to evaluate the safety and efficacy of remdesivir compared with a remdesivir placebo-control (NCT04280705). NIAID developed this study in part based on the existing Chinese clinical trials in addition to consulting with the WHO.
Gilead Sciences initiated two clinical trials that began in mid-March, comparing remdesivir to standard of care in patients with moderate or severe coronavirus disease (COVID-19) in an open-label, randomized trial, NCT04292899. This trial will explore the safety and efficacy of remdesivir in combination with standard of care to compare study arms of 5- or 10-day remdesivir dosing on the primary outcome of fever and oxygen saturation. NCT04292730 maintains three study arms to compare remdesivir provided over 5 or 10 days, to standard of care alone, with the
primary outcome being the proportion of patients discharged by the 14th day. (This was changed after they couldn't get their initial primary outcome, mortality, as desired)
The WHO announced the SOLIDARITY clinical trial, a four-arm trial comparing remdesivir, lopinavir/ritonavir, lopinavir/ritonavir with interferon-β1a, and chloroquine or hydroxychloroquine (ISRCTN83971151). With the goal of reducing trial design time and start-up, the WHO seeks to rapidly facilitate comparison of treatments on a worldwide scale. Data will be analyzed on an interim basis by an independent group of experts, the Global Data and Safety Monitoring Committee, enabling the modification of study design if particular treatments show early promise.
This trial has largely proven the ineffectiveness of Remdesivir (across 70 participant countries). I don't know what more evidence you are looking for.
I have posted an image of some of the trials initiated worldwide - may not include then all though.
Quote:
Originally Posted by proton I
I wanted to give that empirical reference, because it made sense, but others have already advised against giving these uncurated citations. However, some information is better than nothing, so here goes, and I hope no one ever needs to use it, but if the occasion arises, I also hope it helps in making an informed decision (that's another Pandora's Box in the litigation scene, I know). |
That "empirical" reference actually makes no sense, because the writer has not understood the mode of action of Remdesivir. It DOES INHIBIT the RNA dependant RNA polymerase, which he seems to be looking for! While something is better than nothing as a general rule, half baked and half true (or maybe even fake) information is worse than no information at all.
Quote:
Originally Posted by proton Quote
It is a RNA virus which uses reverse transcriptase to convert the RNA to DNA which integrates with human DNA and starts replicating, eventually the host cell dies and thousands of virions get ready to attack thousands more cells. https://techenclave.com/threads/what...9/post-2196696
From what I can understand from different posts, HCQS, Remdesivir all act in preventing the virus from breaking out from cells by increasing the zinc barriers they form in the cell walls. However, the virus increases its replicating capacity and overwhelms these barriers, rendering these drugs useless. Unless a replicasing inhibitor is found, all the future treatments that focus on preventing cell barrier improvement, will also prove to become ineffective.
Please correct me if I'm wrong in my layman understanding of the mechanics of the process. I'm not going to protest any injury to my ego: it's more important to get the right information. |
Viral genome replication is mediated by the viral replication complex, which includes an RNA-dependent RNA polymerase (RdRp), helicase, exonucleaseN, and other accessory proteins. Subsequent assembly of viral nucleocapsids from the packaged viral genomes and translated viral structural proteins occurs at the endoplasmic reticulum-Golgi intermediate compartment, with infectious virions then released from the cell through exocytosis. Viral replication by "reverse transcription" is nothing new and we have several reverse transcriptase inhibitors that have been spectacular in success against HIV, Hep B Hep C, which use the same process for replication. So, the "replicase inhibitors" you are looking for are nothing new.
Remdesivir’s antiviral activity, sterically interacting with the viral RdRp to induce delayed chain termination, has been demonstrated in vitro against multiple coronaviruses (SARS, MERS, contemporary human CoV and bat-CoVs). However, in vitro (conducted on cell cultures in labs) results are not always reproducible in vivo (inside the human body). There is no mention about any zinc barriers in literature. I hope that's clear now.
Now look at this. Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase, and effective against all subtypes and strains of influenza viruses including ones sensitive or resistant to marketed neuraminidase and M2 inhibitors. Favipiravir demonstrated anti-viral activities against other RNA viruses. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome.
When this drug, with a similar mode of action, is available in an oral form at cheaper cost, why is it all about Remdesivir? After all, this drug has also received FDA EUA and DGCA approval for clinical use in Covid 19. Think about it.